# The $480,000 Price Tag on Cancer Drugs Reflects a Troubling Industry Shift
Revolution Medicines released Rasonque this year as a pancreatic cancer treatment, priced at $480,000 annually. The drug exemplifies a broader transformation in oncology pricing that has accelerated dramatically over the past twenty years.
Pancreatic cancer remains among the deadliest malignancies. Median survival after diagnosis hovers around twelve months without treatment. Any therapy that extends life carries weight for patients and their families facing limited options. Rasonque targets KRAS mutations, a genetic alteration present in roughly ninety percent of pancreatic cancers. The specificity of this approach addresses a real clinical need.
Yet the price tells a different story about how the pharmaceutical industry values cancer treatments today.
Two decades ago, cancer drugs cost between $20,000 and $30,000 annually. Today, new cancer therapies routinely launch at $150,000 to $300,000 per year. Rasonque at $480,000 represents the upper edge of this range, but it no longer shocks the market. The inflation far outpaces general healthcare cost growth or drug development inflation.
The industry argues that cancer drug development requires substantial investment. Bringing a new oncology therapy to market costs billions and takes over a decade. Manufacturing precision drugs targeting specific mutations demands expensive infrastructure. These arguments hold some truth. Yet pricing does not correlate neatly with development costs or clinical benefit.
Patients and health systems face genuine hardship from these prices. Insurance coverage varies widely. Some patients exhaust financial resources seeking treatment. Hospital formulary committees must choose between new therapies and other essential services. Medicare negotiation authority, granted recently under inflation reduction legislation, may pressure prices downward, but the process moves slowly.
The mechanism of Rasonque itself reflects modern cancer science. The drug inhibits KRAS proteins that drive tumor growth in pancreatic cancer. This targeted approach replaced older chemotherapy regimens that attacked all dividing cells indiscriminately. Targeted therapies offer better side effect profiles and sometimes superior survival outcomes. Patients benefit from this scientific progress.
But the price structure disconnects from patient benefit in visible ways. Rasonque extends median survival by roughly six months in clinical trials. That translates to $80,000 per month of added life. Other cancer drugs cost even more per unit of survival gained. Meanwhile, insulin, also developed decades ago, costs more today than when it launched, despite no therapeutic improvements.
The $480,000 annual price point signals where oncology pricing heads. Newer targeted therapies, especially those addressing rare cancer subtypes, will likely command similar or higher prices. Combination therapies may push costs even higher. Without regulatory intervention, the pattern continues.
For patients with pancreatic cancer, Rasonque offers a real option where few existed before. The drug's specificity represents genuine scientific progress. Yet the price reflects not innovation cost alone but also what the market will bear. Insurance companies and government programs struggle to absorb these costs without reducing access to other treatments.
The normalization of $400,000-plus cancer drug prices represents a fundamental shift in healthcare economics. This shift demands scrutiny from policymakers, payers, and patients themselves.